Home/Pipeline/CBP-1019

CBP-1019

Oncology (vs. TOP1 inhibitor ADCs)

Phase 1/2Active

Key Facts

Indication
Oncology (vs. TOP1 inhibitor ADCs)
Phase
Phase 1/2
Status
Active
Company

About Coherent Biopharma

A clinical-stage biotech company developing bi-targeting XDC drugs to treat cancer and address undruggable targets.

View full company profile

Therapeutic Areas